We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Edan Instruments

EDAN Instruments manufactures and distributes diagnostic medical equipments in the areas of obstetrics & gynecology, ... read more Featured Products: More products

Download Mobile App





EDAN Takes its Solutions up a Notch at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022

EDAN Instruments, Inc. More...

(Shenzhen, China) is demonstrating its range of latest innovations at MEDICA, the premiere global medical trade show being held at Dusseldorf, Germany, from Nov. 14 to 17, 2022. The company is presenting five new products to more than 120,000 visitors from over 150 countries at the world’s largest trade fair for the medical sector.

For the laboratory sector, EDAN is showcasing its combined range of POCT and IVD innovations at its booth this year, including the ClariLight CL30, its first molecular diagnostics solution. The ClariLight CL30 is a new point of care (POC) molecular diagnostics analysis system based on Loop-Mediated Isothermal Amplification (LAMP) that provides on-the-spot results and empowers physicians for early infectious disease diagnostics, thanks to its agility, speed and flexibility. ClariLight CL30 is designed to offer effective solutions for infectious disease diagnostics by reducing the window period. Unlike PCR-based methods (generally non-portable, laboratory setting, time-consuming), CL30 produces molecular results as quick as 15 minutes, while multi-parameters cartridges and the extraction-free procedure allow massive and rapid molecular tests feasible.

At MEDICA 2022, EDAN is also showcasing iX Series, its next-generation patient monitor that comes with a widescreen design and optimized workflow. Its innovative non-invasive technologies and selective clinical tools contribute to more efficient patient monitoring. Visitors to EDAN’s booth at MEDICA 2022 can experience two ready-to-launch products from the company, including the fully-automated electrocardiograph SE-1201 Pro, and the Holter ECG & ABP 2-in-1 wearables SA-20, tailored for the diagnosis of cardiogenic hypertension. In the obstetrics & gynecology area, EDAN is presenting its portable biofeedback and stimulation system, PA4 Pro, which allows physiotherapists to deliver pelvic floor muscular assessment and treatment flexibly in any scenario. For the first time, EDAN is also exhibiting the upgraded version of Acclarix LX9 alongside its technologically upgraded transducers.

"The highlight is our first molecular diagnostics solution, ClariLight CL30. We are glad to see that most clients are attracted by its rapid results as quick as 15 minutes," said Bo Wang, IVD & POCT Marketing Manager at EDAN.

"A rolling stone gathers no moss. Our breakthrough is visible," said Alex You, Senior Director of EDAN Global Marketing & Strategic Operations, after having a dialogue on EDAN's global development plan with Mr. Wolfram Nikolaus Diener, President & CEO of Messe Dusseldorf GmbH. "And we will go further with a steady stream to advance in our journey towards improving human living conditions."

Related Links:
EDAN Instruments, Inc.


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.